Arthneeti
S

Shalby Ltd

Q4 FY25Healthcare Services

Shalby Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹155
Market cap₹1.7K Cr
P/E42.0
Updated26 Aug 2026
Read4 min read

The short version

Hospital business expected to grow at double-digit rates, maintaining 5-7 years’ growth trend. Hospital business expected to grow at double-digit rates for next 5-7 years due to unutilized capacity and ongoing expansions (Shanay Shah, Page 11).

From Shalby Ltd's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Hospital business expected to grow at double-digit rates, maintaining 5-7 years’ growth trend.
  • Sanar Hospital (newer business) anticipated to grow at higher double-digit rates until capacity is exhausted.
  • Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year.
  • Two new implant products planned to launch in FY '26, expected to add INR40-50 crores yearly revenue after regulatory approvals.
  • Long-term implant product pipeline includes 5-6 products, given a roughly 3-year gestation period per product.
  • Overall consolidated revenue for FY '26 expected to see high single-digit growth or better compared to FY '25.

2 more points from Shalby Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Shalby Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Shalby is expanding capacity in ROCE-accretive businesses.
  • Recent large acquisition of nearly INR 300 crores in last 15 months.
  • Adding a hospital in Mumbai with an investment of over INR 250 crores.
  • Sanar hospital optional bed expansion from 130 to 180 beds planned; timelines depend on occupancy and approvals.
  • Franchisee business growing selectively with focus on quality partnerships; minimal capital employed but requires management bandwidth.
  • Implant business investing significantly for growth; product development and regulatory approvals ongoing.

2 more points from Shalby Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Aster DM Quality Care Ltd
Rev 2Mar 1
3
Rev 2Mar 2
4
Rev 2Mar 3
5
Rev 2Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript on page 15 of Shalby Limited's Q4 FY '25 earnings call does not provide a specific figure or detailed commentary on the current or expected order book or pending orders. Key points related to business growth and outlook include: - Hospital business expected to continue double-digit growth. - Implant business anticipated to grow at higher double-digit rates due to a lower base. - Implant segment grew approximately 50% on a 12-month consolidated basis in FY '25. - Launch of two new implant products planned, potentially contributing INR40-50 crores annually.

2 more points from Shalby Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Shalby Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shalby's management said in earlier quarters

Others in Healthcare Services this season

  • 3B Blackbio (Q4 FY25)

    UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…

  • Apollo Hospitals (Q4 FY25)

    . Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Suraksha Diagno. (Q4 FY25)

    Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…

  • Narayana Hrudayalaya Ltd (Q4 FY25)

    Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…

Compare:vs Apollo Hospitalsvs Manipal Health Enterprises Ltdvs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shalby Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shalby Ltd Q4 FY25 results?

Hospital business expected to grow at double-digit rates, maintaining 5-7 years’ growth trend. Hospital business expected to grow at double-digit rates for next 5-7 years due to unutilized capacity and ongoing expansions (Shanay Shah, Page 11).

What is Shalby Ltd share price analysis?

Shalby Ltd currently shows a neutral. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shalby Ltd planning capital expenditure?

Shalby is expanding capacity in ROCE-accretive businesses.

Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.